{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:57:43Z","timestamp":1764305863411,"version":"3.37.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40265-021-01506-0","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T10:11:23Z","timestamp":1623233483000},"page":"971-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-6814","authenticated-orcid":false,"given":"Wanyuan","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-4963","authenticated-orcid":false,"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"9483","key":"1506_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397\u2013408.","journal-title":"Lancet"},{"issue":"2","key":"1506_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0019-5278.146897","volume":"18","author":"C Bianchi","year":"2014","unstructured":"Bianchi C, Bianchi T. Global mesothelioma epidemic: trend and features. Indian J Occup Environ Med. 2014;18(2):82\u20138.","journal-title":"Indian J Occup Environ Med."},{"issue":"Suppl 1","key":"1506_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.lungcan.2005.03.002","volume":"49","author":"L Kazan-Allen","year":"2005","unstructured":"Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer. 2005;49(Suppl 1):S3-8.","journal-title":"Lung Cancer"},{"issue":"8","key":"1506_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475\u201388.","journal-title":"Nat Rev Cancer."},{"key":"1506_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CLEP.S105396","volume":"8","author":"JL Beebe-Dimmer","year":"2016","unstructured":"Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743\u201350.","journal-title":"Clin Epidemiol."},{"key":"1506_CR6","unstructured":"Office for National Statistics. Mesothelioma deaths by local authority, England and Wales, registered between 2015 and 2017. 2019. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/adhocs\/009926mesotheliomadeathsbylocalauthorityenglandandwalesregisteredbetween2015and2017. Accessed 10 Nov 2020."},{"issue":"6","key":"1506_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000486578","volume":"95","author":"G Carioli","year":"2018","unstructured":"Carioli G, Bonifazi M, Rossi M, Zambelli A, Franchi M, Zocchetti C, et al. Management and survival of pleural mesothelioma: a record linkage study. Respiration. 2018;95(6):405\u201313.","journal-title":"Respiration"},{"issue":"1","key":"1506_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1183\/09031936.00153611","volume":"40","author":"RA Damhuis","year":"2012","unstructured":"Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J. 2012;40(1):185\u20139.","journal-title":"Eur Respir J."},{"key":"1506_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.lungcan.2018.10.009","volume":"125","author":"M Rosskamp","year":"2018","unstructured":"Rosskamp M, Macq G, Nackaerts K, Praet M, Van Eycken L, Van Meerbeeck JP, et al. Real-life treatment practice for malignant pleural mesothelioma in Belgium. Lung Cancer. 2018;125:258\u201364.","journal-title":"Lung Cancer"},{"issue":"7","key":"1506_CR10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"AS Mansfield","year":"2014","unstructured":"Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, et al. B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9(7):1036\u201340.","journal-title":"J Thorac Oncol."},{"issue":"8","key":"1506_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763\u201372.","journal-title":"Lancet Oncol."},{"issue":"9948","key":"1506_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","volume":"384","author":"RC Rintoul","year":"2014","unstructured":"Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118\u201327.","journal-title":"Lancet"},{"issue":"14","key":"1506_CR13","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol."},{"issue":"10026","key":"1506_CR14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314.","journal-title":"Lancet"},{"issue":"15_suppl","key":"1506_CR15","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2020.38.15_suppl.9004","volume":"38","author":"M Pagano","year":"2020","unstructured":"Pagano M, Ceresoli G, Zucali P, Pasello G, Garassino MC, Grosso F, et al. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): results of Italian Rames Study. J Clin Oncol. 2020;38(15_suppl):9004.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1506_CR16","doi-asserted-by":"publisher","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","volume":"4","author":"H Ujiie","year":"2015","unstructured":"Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4(6):e1009285.","journal-title":"Oncoimmunology."},{"issue":"5","key":"1506_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrc3498","volume":"13","author":"M Holzel","year":"2013","unstructured":"Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013;13(5):365\u201376.","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"1506_CR18","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedres","year":"2015","unstructured":"Cedres S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE. 2015;10(3):e0121071.","journal-title":"PLoS ONE"},{"key":"1506_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","volume":"52","author":"C Combaz-Lair","year":"2016","unstructured":"Combaz-Lair C, Galateau-Salle F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, et al. Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016;52:9\u201318.","journal-title":"Hum Pathol."},{"issue":"17","key":"1506_CR20","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889\u201394.","journal-title":"J Clin Oncol."},{"issue":"8","key":"1506_CR21","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100(8):4712\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"14","key":"1506_CR22","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100(14):8372\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"1506_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AV Maker","year":"2006","unstructured":"Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29(4):455\u201363.","journal-title":"J Immunother."},{"issue":"36","key":"1506_CR24","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","volume":"26","author":"JS Weber","year":"2008","unstructured":"Weber JS, O\u2019Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I\/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950\u20136.","journal-title":"J Clin Oncol."},{"issue":"11","key":"1506_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","volume":"14","author":"L Calabro","year":"2013","unstructured":"Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104\u201311.","journal-title":"Lancet Oncol."},{"issue":"4","key":"1506_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","volume":"3","author":"L Calabro","year":"2015","unstructured":"Calabro L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301\u20139.","journal-title":"Lancet Respir Med."},{"issue":"9","key":"1506_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabro L, Aerts J, Perez SC, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261\u201373.","journal-title":"Lancet Oncol."},{"issue":"5","key":"1506_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623\u201330.","journal-title":"Lancet Oncol."},{"issue":"10","key":"1506_CR29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1569\u201376.","journal-title":"J Thorac Oncol."},{"issue":"18","key":"1506_CR30","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, et al. clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485\u201392.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"1506_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","volume":"5","author":"R Hassan","year":"2019","unstructured":"Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(3):351\u20137.","journal-title":"JAMA Oncol."},{"issue":"12","key":"1506_CR32","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","volume":"31","author":"S Popat","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O\u2019Brien M, Pope A, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734\u201345.","journal-title":"Ann Oncol."},{"key":"1506_CR33","unstructured":"Fennell DA, Ottensmeier C, Califano R, Hanna G, Ewings S, Hill K, et al. Nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM Phase 3 trial. In: Presented at International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer; January 28\u201331, 2021; Virtual. Abstract PS01.11."},{"issue":"6","key":"1506_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabro","year":"2018","unstructured":"Calabro L, Morra A, Giannarelli D, Amato G, D\u2019Incecco A, Covre A, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451\u201360.","journal-title":"Lancet Respir Med."},{"issue":"3","key":"1506_CR35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260\u201370.","journal-title":"Lancet Respir Med."},{"issue":"2","key":"1506_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239\u201353.","journal-title":"Lancet Oncol."},{"issue":"10272","key":"1506_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao A, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375\u201386.","journal-title":"The Lancet."},{"issue":"22","key":"1506_CR38","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med."},{"issue":"24","key":"1506_CR39","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med."},{"issue":"21","key":"1506_CR40","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med."},{"issue":"9","key":"1506_CR41","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","volume":"21","author":"AK Nowak","year":"2020","unstructured":"Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213\u201323.","journal-title":"Lancet Oncol."},{"issue":"9","key":"1506_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/thorax.55.9.731","volume":"55","author":"JG Edwards","year":"2000","unstructured":"Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O\u2019Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731\u20135.","journal-title":"Thorax"},{"key":"1506_CR43","doi-asserted-by":"crossref","unstructured":"Reck M, Ciuleanu T-E, Cobo Dols M, Schenker M, Zurawski B, Menezes J, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV\/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020;38.","DOI":"10.1200\/JCO.2020.38.15_suppl.9501"},{"key":"1506_CR44","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020\u201331.","journal-title":"N Engl J Med."},{"issue":"6230","key":"1506_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"5","key":"1506_CR46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33(5):843-52 e4.","journal-title":"Cancer Cell"},{"issue":"25","key":"1506_CR47","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to pd-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med."},{"issue":"1","key":"1506_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol."},{"key":"1506_CR49","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. Accessed 12 Dec 2020."},{"key":"1506_CR50","doi-asserted-by":"crossref","unstructured":"Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017.","DOI":"10.1200\/PO.17.00073"},{"issue":"10","key":"1506_CR51","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","volume":"13","author":"S Arulananda","year":"2018","unstructured":"Arulananda S, Thapa B, Walkiewicz M, Zapparoli GV, Williams DS, Dobrovic A, et al. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1588\u201394.","journal-title":"J Thorac Oncol."},{"issue":"10","key":"1506_CR52","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","volume":"59","author":"N Yamada","year":"2010","unstructured":"Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59(10):1543\u20139.","journal-title":"Cancer Immunol Immunother."},{"issue":"9","key":"1506_CR53","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","volume":"193","author":"R Cornelissen","year":"2016","unstructured":"Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, Hendriks RW, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016;193(9):1023\u201331.","journal-title":"Am J Respir Crit Care Med."},{"issue":"12","key":"1506_CR54","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","volume":"181","author":"JP Hegmans","year":"2010","unstructured":"Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181(12):1383\u201390.","journal-title":"Am J Respir Crit Care Med."},{"issue":"11","key":"1506_CR55","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.4049\/jimmunol.1102209","volume":"187","author":"C Alfaro","year":"2011","unstructured":"Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, de Sanmamed MF, Sangro B, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol. 2011;187(11):6130\u201342.","journal-title":"J Immunol."},{"key":"1506_CR56","doi-asserted-by":"crossref","unstructured":"Minchom A, Yuan W, Crespo M, Gurel B, Figueiredo I, Wotherspoon A, et al. Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. J Immunother Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2020-000713"},{"issue":"2","key":"1506_CR57","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol. 2019;14(2):276\u201387.","journal-title":"J Thorac Oncol."},{"issue":"6","key":"1506_CR58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/cancers11060831","volume":"11","author":"A Catino","year":"2019","unstructured":"Catino A, de Gennaro G, di Gilio A, Facchini L, Galetta D, Palmisani J, et al. Breath analysis: a systematic review of volatile organic compounds (VOCs) in diagnostic and therapeutic management of pleural mesothelioma. Cancers. 2019;11(6):831.","journal-title":"Cancers"},{"issue":"5","key":"1506_CR59","doi-asserted-by":"publisher","first-page":"520","DOI":"10.21037\/tlcr.2018.04.09","volume":"7","author":"L Brusselmans","year":"2018","unstructured":"Brusselmans L, Arnouts L, Millevert C, Vandersnickt J, van Meerbeeck JP, Lamote K. Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review. Transl Lung Cancer Res. 2018;7(5):520\u201336.","journal-title":"Transl Lung Cancer Res."},{"issue":"14","key":"1506_CR60","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1200\/JCO.19.02446","volume":"38","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1positive, advanced nonsmall-cell lung cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020;38(14):1580\u201390.","journal-title":"J Clin Oncol."},{"key":"1506_CR61","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2018.06.005","volume":"101","author":"A Bernard-Tessier","year":"2018","unstructured":"Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, et al. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018;101:160\u20134.","journal-title":"Eur J Cancer."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01506-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01506-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01506-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T20:28:37Z","timestamp":1675456117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01506-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01506-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"type":"print","value":"0012-6667"},{"type":"electronic","value":"1179-1950"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"17 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Cui reports research grant funding from the Breast Cancer Trials group and the Australian Government Research Training scholarship, outside of the submitted work. Prof. Popat reports personal fees from AstraZeneca, Roche, Boehringer Ingelheim, Pfizer, Novartis, Takeda, BMS, MSD, EMD Serono, Bayer, Blueprint, Daiichi Sankyo, Guardant Health, Janssen, GSK, BeiGene, Incyte, Eli Lilly, Amgen, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WC literature search, tables, data interpretation, writing. SBP data interpretation, writing, supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}